R)-2-Hydroxy-N-(4-nitrophenethyl)-2-phenylacetamide is a chiral pharmaceutical intermediate associated with the synthesis of Mirabegron. It contains a stereochemically defined hydroxyphenylacetamide structure and a nitrophenethyl group, making it a relevant compound for pharmaceutical synthesis and process development.
Chemox Pharma offers pharmaceutical intermediates for B2B sourcing, subject to product availability, quality requirements, and applicable commercial specifications.
R)-2-Hydroxy-N-(4-nitrophenethyl)-2-phenylacetamide is a chiral pharmaceutical intermediate associated with the synthesis of Mirabegron. It contains a stereochemically defined hydroxyphenylacetamide structure and a nitrophenethyl group, making it a relevant compound for pharmaceutical synthesis and process development.
Chemox Pharma offers pharmaceutical intermediates for B2B sourcing, subject to product availability, quality requirements, and applicable commercial specifications.
This compound is a pharmaceutical intermediate, not the therapeutic API itself. It does not have an established therapeutic mechanism of action as a standalone medicine.
Mirabegron, the associated API, acts as a beta-3 adrenergic receptor agonist. It relaxes the detrusor smooth muscle of the urinary bladder during the storage phase and is used in the management of overactive bladder.
It is a pharmaceutical intermediate associated with Mirabegron synthesis.
Its molecular formula is C16H16N2O4, with a molecular weight of approximately 300.31 g/mol.
No. It is a distinct chemical intermediate and should not be confused with the finished active pharmaceutical ingredient.
Sample availability, quantity, documentation, and dispatch arrangements can be confirmed with the Chemox Pharma sales team.
Applicable documents may include a Certificate of Analysis (CoA), Safety Data Sheet (SDS), and other quality documents, subject to availability and customer requirements.
Use the storage conditions specified in the current SDS and approved product specification. Do not assume a temperature range without product-specific data.
2-(((3aR,4S,6R,6aS)-6-((5-Amino-6-chloro-2-(propylthio)pyrimidin-4-yl)amino)-2,2-dimethyltetrahydro-3aH-cyclopenta[d][1,3]dioxol-4-yl)oxy)ethanol is a Ticagrelor-related pharmaceutical intermediate
5-(Difluoromethoxy)-2-mercapto-1H-benzimidazole is a benzimidazole-based pharmaceutical intermediate used in the synthesis of Pantoprazole and related pharmaceutical compounds. Its chemical structure contains a difluoromethoxy
(R)-2-(2-Aminothiazol-4-yl)-N-(2-(2-((2-hydroxy-2-phenylethyl)amino)ethyl)phenyl)acetamide is a structurally related compound associated with Mirabegron and is also identified in chemical references as ortho-Mirabegron. This compound may be
